The RATIO study: Oral contraceptives and the risk of peripheral arterial disease in young women

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 3, 2003, Pages 439-444

  Van Den Bosch, M A A J ^a   Kemmeren, J M ^a   Tanis, B C ^b   Mali, Y W P T M ^c   Helmerhorst, Z F M ^d   Rosendaal, F R ^b   Algra, A ^a   Van Der Graaf, Y ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Department of Obstetrics Gynecology and Reproductive Medicine   (Netherlands)

Author keywords

Epidemiology; Oral contraceptives; Peripheral arterialdisease; Risk factors

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; FEMALE; HUMAN; MIDDLE AGED; NETHERLANDS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; QUESTIONNAIRE; RISK; RISK FACTOR;

ADULT; ARTERIAL OCCLUSIVE DISEASES; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PERIPHERAL VASCULAR DISEASES; PROGESTINS; QUESTIONNAIRES; RISK FACTORS;

EID: 0141928038     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00079.x     Document Type: Article

References (32)

1. Stadel BV. Oral contraceptives and cardiovascular disease (first of two parts). N Engl J Med 1981; 305: 612-8.
2. Stadel BV. Oral contraceptives and cardiovascular disease (second of two parts). N Engl J Med 1981; 305: 672-7.
3. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988; 319: 1313-7.
4. Royal College of General Practitioners. Mortality among oral-contraceptive users. Lancet 1977; 348: 727-31.
5. Royal College of General Practitioners. Further analysis of mortality in oral contraceptive users. Lancet 1981; i: 541-6.
6. Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375-81.
7. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
8. WHO collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82.
9. WHO collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low estrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8.
10. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
11. Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127-8.
12. Wahl P, Walden C, Knopp R, Hoover J, Wallace R, Heiss G, Rifkind B. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983; 308: 862-7.
13. De Bakey ME, Crawford ES, Garrett HE, Cooley DA, Morris GC, Abbott JP. Occlusive disease of the lower extremities in patients 16-37 years of age. Ann Surg 1964; 159: 873-90.
14. Gagne PJ, Vitti MJ, Fink LM, Duncan J, Nix ML, Barnes RW, Hauer-Jensen M, Barone GW, Eidt JF. Young women with advanced aortoiliac occlusive disease: new insights. Ann Vasc Surg 1996; 10: 546-57.
15. Jick SS, Vasilakis C, JickH. Pregnancies and terminations after 1995 warning about third generation oral contraceptives. Lancet 1998; 351: 1404.
16. Friedman SA, Holling HE, Roberts B. Etiologic factors in aortoiliac and femoropopliteal vascular disease. The Leriche syndrome. N Engl J Med 1964; 271: 1382-5.
17. Hartge P, Brinton LA, Rosenthal JF, Cahill JI, Hoover RN, Waksberg J. Random Digit Dialing in selecting a population-based control group. Am J Epidemiol 1984; 120: 825-33.
18. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997; 349: 1202-9.
19. WHO collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996; 348: 498-505.
20. Lewis MA, Spitzer WO, Heineman LAJ, MacRae KD, Bruppacher R, Thorogood M. Transnational Research Group on Oral Contraceptives and the Health of Young women. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Br Med J 1996; 312: 88-90.
21. Lewis MA, Heinemann LAJ, Spizer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Research Group on oral contraceptives and the health of young women. Contraception 1997; 56: 129-40.
22. Dunn N, Thorogood M, Faragher B, Caestecker de L, MacDonald TM, McCollum C. Oral contraceptives and myocardial infarction: results of the MICA case-control study. Br Med J 1999; 318: 1579-84.
23. Vandenbroucke JP. Cerebral sinus thrombosis and oral contraceptives: There are limits to predictability. Br Med J 1998; 317: 483-4.
24. Schwartz SM, Siscovick DS, Longstreth WT, Psaty BM, Beverly RK, Raghunathan TE, Lin D, Koepsell TD. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med 1997; 127: 596-603.
25. Danforth D, Manolo-Estrela P, Buckingham JC. The effect of pregnancy and of Enovid on the rabbit vasculature. Am J Obstet Gynec 1964; 88: 952-62.
26. Irey NS, Manion WC, Taylor HB. Vascular lesions in women taking oral contraceptives. Arch Pathol 1970; 89: 1-8.
27. Van Vroonhoven TJMV. Intermittent claudication in premenopausal women: a correlation with the long-term use of oral contraceptives? J Cardiovas Surg 1977; 18: 291-5.
28. Sulistiyani Adelman SJ, Chandrasekaran A, Jayo J, Clair RW. Effect of 17a-dihydroequilin sulfate, a conjugated equine estrogen, and ethinylestradiol on atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 837-46.
29. Bellinger DA, Williams JK, Adams MR, Honore EK, Bender DE. Oral contraceptives and hormone replacement therapy do not increase the incidence of arterial thrombosis in a nonhuman primate model. Arterioscler Thromb Vasc Biol 1998; 18: 92-9.
30. Nischan P, Ebeling K, Thomas DB, Hirsch U. Comparison of recalled and validated oral contraceptive histories. Am J Epidemiol 1993; 138: 697-703.
31. Hunter DJ, Manson JE, Colditz GA, Chasan-Taber L, Troy L, Stampfer MJ, Speizer FE, Willett WC. Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US women. Contraception 1997; 56: 373-8.
32. Slone D, Shapiro S, Kaufmann DW, Rosenberg L, Miettinen OS, Stolley PD. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 1981; 305: 420-4.